Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Nektar Therapeutics's profit margin for the twelve months ending Dec 31, 2025 was -297.1%. For fiscal 2025 it was -297.1%, against -120.9% the year before. The highest annual figure on record is 57.1% in fiscal 2018.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -297.1% | −176.2 |
| FY2024 | Dec 31, 2024 | -120.9% | +185.5 |
| FY2023 | Dec 31, 2023 | -306.3% | +93.7 |
| FY2022 | Dec 31, 2022 | -400.0% | +114.1 |
| FY2021 | Dec 31, 2021 | -514.0% | −223.4 |
| FY2020 | Dec 31, 2020 | -290.6% | +93.8 |
| FY2019 | Dec 31, 2019 | -384.5% | −441.6 |
| FY2018 | Dec 31, 2018 | 57.1% | +88.5 |
| FY2017 | Dec 31, 2017 | -31.4% | +61.4 |
| FY2016 | Dec 31, 2016 | -92.8% | −57.6 |
| FY2015 | Dec 31, 2015 | -35.2% | −8.3 |
| FY2014 | Dec 31, 2014 | -26.9% | +81.9 |
| FY2013 | Dec 31, 2013 | -108.8% | +102.9 |
| FY2012 | Dec 31, 2012 | -211.7% | −24.2 |
| FY2011 | Dec 31, 2011 | -187.4% | −163.6 |
| FY2010 | Dec 31, 2010 | -23.9% | +118.7 |
| FY2009 | Dec 31, 2009 | -142.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -165.4% | −190.3 |
| Q3 FY2025 | Sep 30, 2025 | -301.3% | −147.7 |
| Q2 FY2025 | Jun 30, 2025 | -372.2% | −149.3 |
| Q1 FY2025 | Mar 31, 2025 | -486.4% | −316.4 |
| Q4 FY2024 | Dec 31, 2024 | 24.9% | +201.1 |
| Q3 FY2024 | Sep 30, 2024 | -153.6% | +36.2 |
| Q2 FY2024 | Jun 30, 2024 | -222.9% | +26.5 |
| Q1 FY2024 | Mar 31, 2024 | -170.1% | +464.4 |
| Q4 FY2023 | Dec 31, 2023 | -176.2% | +94.9 |
| Q3 FY2023 | Sep 30, 2023 | -189.8% | +60.1 |
| Q2 FY2023 | Jun 30, 2023 | -249.4% | +487.5 |
| Q1 FY2023 | Mar 31, 2023 | -634.5% | −270.4 |
| Q4 FY2022 | Dec 31, 2022 | -271.0% | +311.3 |
| Q3 FY2022 | Sep 30, 2022 | -249.9% | +270.5 |
| Q2 FY2022 | Jun 30, 2022 | -736.9% | −293.9 |
| Q1 FY2022 | Mar 31, 2022 | -364.2% | +155.8 |
| Q4 FY2021 | Dec 31, 2021 | -582.4% | −82.8 |
| Q3 FY2021 | Sep 30, 2021 | -520.5% | −158.9 |
| Q2 FY2021 | Jun 30, 2021 | -443.1% | −279.3 |
| Q1 FY2021 | Mar 31, 2021 | -520.0% | −245.9 |
| Q4 FY2020 | Dec 31, 2020 | -499.5% | −168.3 |
| Q3 FY2020 | Sep 30, 2020 | -361.6% | −24.1 |
| Q2 FY2020 | Jun 30, 2020 | -163.8% | +309.2 |
| Q1 FY2020 | Mar 31, 2020 | -274.2% | +149.7 |
| Q4 FY2019 | Dec 31, 2019 | -331.2% | −84.6 |
| Q3 FY2019 | Sep 30, 2019 | -337.4% | +8.9 |
| Q2 FY2019 | Jun 30, 2019 | -473.0% | −562.3 |
| Q1 FY2019 | Mar 31, 2019 | -423.9% | −171.9 |
| Q4 FY2018 | Dec 31, 2018 | -246.6% | −211.2 |
| Q3 FY2018 | Sep 30, 2018 | -346.3% | −386.1 |
| Q2 FY2018 | Jun 30, 2018 | 89.3% | +262.4 |
| Q1 FY2018 | Mar 31, 2018 | -252.0% | +6.3 |
| Q4 FY2017 | Dec 31, 2017 | -35.4% | +77.2 |
| Q3 FY2017 | Sep 30, 2017 | 39.8% | +158.8 |
| Q2 FY2017 | Jun 30, 2017 | -173.1% | −24.8 |
| Q1 FY2017 | Mar 31, 2017 | -258.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -112.7% | – |
| Q3 FY2016 | Sep 30, 2016 | -119.0% | – |
| Q2 FY2016 | Jun 30, 2016 | -148.3% | – |
See a number that looks wrong?